(Q37832129)

24 August 2017

1 reference

title

Hepatotoxicity related to antirheumatic drugs (English)

1 reference

24 August 2017

1 reference

Guruprasad P Aithal

1

0 references

language of work or name

English

0 references

publication date

25 January 2011

1 reference

Nature Reviews Rheumatology

24 August 2017

published in

1 reference

24 August 2017

volume

7

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

139-150

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2010.214

24 August 2017

exact match

0 references

cites work

Concordance of the toxicity of pharmaceuticals in humans and in animals

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Acute and clinically relevant drug-induced liver injury: a population based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Nonsteroidal anti-inflammatory drug-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

A common ABCC2 promoter polymorphism is not a determinant of the risk of spina bifida

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

The danger hypothesis--potential role in idiosyncratic drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Idiosyncratic drug hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Vanishing bile duct syndrome in drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Monitoring methotrexate toxicity in juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Toward a better understanding of methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Drugs affecting homocysteine metabolism: impact on cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Homocysteine, the bad thiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

ER stress and lipogenesis: a slippery slope toward hepatic steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Methotrexate and histologic hepatic abnormalities: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

ER stress: can the liver cope?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Nodular regenerative hyperplasia: not all nodules are created equal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Hepatic manifestations of autoimmune rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Biologic therapies in rheumatology: lessons learned, future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Serious liver disease induced by infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Outcome and prognostic markers in severe drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Psoriasis and its management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Prolonged cholestasis and ductopenia following gold salt therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Fatal hepatic necrosis associated with parenteral gold therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Dangerous liaisons: drug, host and the environment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Noninvasive monitoring for methotrexate hepatotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Preempting and preventing drug-induced liver injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.214

Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions

31 March 2020

1 reference

12 December 2020

The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs

1 reference

12 December 2020

Drug use and toxicity in psoriatic disease: focus on methotrexate

1 reference

12 December 2020

Light- and electron-microscopical study of a case of gold salt-induced hepatotoxicity

1 reference

12 December 2020

Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis.

1 reference

12 December 2020

Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors

1 reference

12 December 2020

Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs - comparison of drugs and adverse reactions

1 reference

12 December 2020

Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2010.214

1 reference

24 August 2017

1 reference